Health state utility data in Cystic Fibrosis: A systematic review

Bishal Mohindru, David Turner, Tracey Sach, Diana Bilton, Siobhan Carr, Olga Archangelidi, Arjun Bhadhuri, Jennifer Whitty

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)
34 Downloads (Pure)


Introduction: Cystic fibrosis (CF) is a life-limiting, hereditable condition, with the highest prevalence in Europe. CF treatments have led to improvements in clinical symptoms, disease management and decelerated disease progression. However, little is known about the health state utility (HSU) associated with CF disease states, adverse events, and changes in disease severity. Although HSU data have contributed to existing health economic modelling studies, a lack of such data have been highlighted. This systematic review aims to provide a summary of HSU-related research in CF and highlight related research gaps. Methods: Online searches were performed in six databases and studies in any of the following categories were included: (1) estimation of HSUs in CF; (2) mapping studies between patient-reported outcome measures (PROMs) and HSUs; (3) economic evaluations on the management of CF that report primary HSU data; and (4) any CF clinical trial that reported HSU as an outcome. Results: A total of 17 studies were reviewed, of which 12 provided HSU values for specific CF populations. The remaining five articles provided HSU data that were broken down by CF relevant health states, including lung transplantations, pulmonary exacerbation (PEx) events and forced expiratory volume in 1 s (FEV 1). Conclusion: Current HSU data in CF are limited and there is considerable scope for further research, both in providing HSU values for CF and in investigating methods for HSU elicitation/evaluation in CF populations.

Original languageEnglish
Pages (from-to)13–25
Number of pages13
JournalPharmacoEconomics - Open
Issue number1
Early online date3 May 2019
Publication statusPublished - 1 Mar 2020

Cite this